Dexibuprofen
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Dexibuprofen: From Musculoskeletal Pain and Inflammation to Ankylosing Spondylitis
Note on candidate selection: TxGNN generated 10 predicted indications for dexibuprofen. Nine of these (ranked #1–#8 and #10 by raw model score) are rated L5 (model prediction only), and the accompanying rationale for each explicitly describes them as mechanistically implausible or likely model noise (e.g. rare skeletal dysplasia syndromes with no inflammatory pathology). Only Ankylosing Spondylitis (rank #9) is supported by actual literature and reaches a meaningful decision stage (S2, L2 evidence). This report therefore focuses on Ankylosing Spondylitis as the only clinically actionable candidate in this evidence pack.
One-Sentence Summary
Dexibuprofen is the active S(+)-enantiomer of ibuprofen, a non-selective COX-1/COX-2 inhibitor used for musculoskeletal pain and inflammation. The TxGNN model predicts it may be effective for Ankylosing Spondylitis, a direction supported by 3 publications, though this largely reflects an established NSAID class effect rather than a novel repurposing mechanism, and no dedicated clinical trials for this pairing are currently registered.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in the regulatory data pack; published literature on dexibuprofen describes use in musculoskeletal pain and inflammatory/degenerative conditions (e.g. rheumatoid arthritis, gonarthrosis, lumbar spine syndrome) |
| Predicted New Indication | Ankylosing Spondylitis |
| TxGNN Prediction Score | 99.70% |
| Evidence Level | L2 |
| UK Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed drug-level mechanism-of-action data is flagged as a data gap in this pack. However, the literature evidence retrieved for this specific pairing (PMID 9013382) identifies dexibuprofen as the active S(+)-enantiomer of ibuprofen, acting as a non-selective COX-1/COX-2 inhibitor — the standard NSAID mechanism.
Ankylosing spondylitis and the other conditions in dexibuprofen’s established evidence base (rheumatoid arthritis, gonarthrosis, lumbar vertebral column syndrome, activated coxarthrosis) share a common inflammatory/degenerative joint pathology. NSAIDs, including dexibuprofen, are already first-line symptomatic therapy across this disease group.
Mechanistically, this prediction is therefore best understood as an extension of an existing NSAID class effect rather than a novel repurposing hypothesis — the pharmacology is well precedented, but no trial has been run to confirm dexibuprofen specifically (as opposed to ibuprofen generally, or other NSAIDs) in a dedicated ankylosing spondylitis population.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 9013382 | 1996 | RCT | Journal of Clinical Pharmacology | Reevaluation of double-blind, randomised studies of dexibuprofen (Seractil) across several conditions including lumbar vertebral column syndrome, rheumatoid arthritis, ankle joint distortion, gonarthrosis, ankylosing spondylitis and activated coxarthrosis; efficacy and safety compared using standardised univariate/multivariate analysis |
| 11771569 | 2001 | Review | Clinical Rheumatology | Overview of 8 GCP clinical trials (1,463 patients), including double-blind studies against placebo, racemic ibuprofen and diclofenac; covers dose-finding, pharmacokinetics, tolerability and compliance, plus a meta-analysis of five trials |
| 21175420 | 2010 | Review | Critical Reviews in Therapeutic Drug Carrier Systems | General review of NSAID drug-delivery (microencapsulation) across arthritis types including osteoarthritis, rheumatoid arthritis, septic arthritis, juvenile idiopathic arthritis and ankylosing spondylitis; not specific to dexibuprofen efficacy data |
UK Market Information
Dexibuprofen currently has no UK marketing authorisation on record in this data pack (market status: Not Marketed; 0 licences). No product-level UK licensing information is available to summarise.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
(Note: key warnings, contraindications and drug-drug interaction data for dexibuprofen were not available in this evidence pack — this is flagged as a Blocking data gap, see below.)
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Ankylosing spondylitis is the only TxGNN-predicted indication for dexibuprofen with any supporting literature, and it aligns with a well-established NSAID class effect in spondyloarthropathy management. However, the supporting studies are decades old (1996–2010), none are specific dedicated trials for this exact indication, no clinical trials are currently registered, and the drug has no current UK marketing authorisation.
To proceed, the following is needed:
- Product label warnings and contraindications (currently a Blocking data gap — required before any S1 safety assessment can proceed)
- Formal DrugBank/SmPC mechanism-of-action record (currently a High-severity data gap)
- A UK-specific regulatory pathway assessment, given the drug is not currently marketed in the UK
- Consideration of whether a dedicated trial in ankylosing spondylitis (rather than reliance on general NSAID class evidence) is warranted before clinical adoption
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.